A survey for patients living with chronic disease.
The Physical Activity Support Kit Initiative (PASKI) is a B.C. province-wide project to develop an online “one-stop shop” of information and resources to help persons living with chronic disease to ‘move more and sit less’.
Ninety-seven patients, researchers and health care providers are working to develop this online toolkit. To help us better understand what patients would most like to see included in the toolkit, we have developed a short (10 minutes) survey.
If you are living with a chronic disease, we would appreciate your input. The survey is open until September 18, 2015, inclusively.
Image courtesy of FrameAngel at FreeDigitalPhotos.net
According to a new study, mental health problems like anxiety and depression may explain why people with rheumatoid arthritis (RA) have an increased risk of cardiovascular disease. According to the study, anger, anxiety, depressive symptoms, job stress and low social support was linked to increasing risk of hardening of the arteries, or atherosclerosis for people with RA.
In the study, Dr. Jon T. Giles of Columbia University College of Physicians and Surgeons in New York City and team compared 195 patients with RA and no history of heart problems to more than 1,000 similar adults without arthritis. Study participants with RA had more depressive symptoms, higher personal (such as caring for a loved one) and health stress, higher job stress and lower relationship stress. These listed psychosocial problems, on top of higher anxiety scores and anger scores, were associated with increased odds of coronary artery calcium. Furthermore, job stress increased the risk of plaque in the carotid artery in the neck, which helps supply blood to the brain. In the comparison group, there was no relation between the aforementioned psychosocial factors and artery calcium. Continue reading →
Image courtesy of nenetus at FreeDigitalPhotos.net
A recent study published in the Journal of Behavioral Medicine suggests that positive attitude is linked to fewer rheumatoid arthritis (RA) symptoms. In the study, the RA patients who reported more positive mood moments during the day had less pain and fewer arthritis-related complications than those who reported greater depressive symptoms. This is the first study to measure mood throughout the day (previous studies linked end-of-day mood to increased/decreased pain among arthritis patients).
People living with RA are twice as likely as the rest of the population to experience depression. There are several reasons depression occurs in people with RA. Sometimes it starts from the shock of diagnosis and finding out that it is an unpredictable disease that can become more painful and debilitating over time. Sometimes depression occurs because of feeling tired and unwell or isolated as a result of the disease. RA can affect the ability to work, look after family, and engage in social activities and interests. The stress that results from either of these situations can trigger depression in those who are predisposed by heredity or other factors. Click here to learn more about depression and arthritis. Continue reading →
Qu’est-ce que le comité ACE a fait pour vous dernièrement ? Voilà ce à quoi nous avons travaillé cet été.
Plan de travail 2015-2016
Pour son plan de travail 2015-2016, le comité ACE s’est fixé des objectifs ambitieux. Nos cinq principaux domaines d’activité assureront une information à grand impact pour les consommateurs, entre autres en ce qui a trait aux listes de médicaments remboursables par les régimes publics ainsi qu’à l’éducation sur les programmes, la défense des intérêts et les tiers payeurs, partout au pays. Continue reading →
ACE has set ambitious goals for its 2015/2016 Work Plan. Our five primary work areas will deliver high impact consumer and public formulary information, programming, advocacy and private payer education across Canada.
BC PharmaCare is looking for your input on denosumab (Prolia®) for the treatment of osteoporosis in men
Denosumab (Prolia®) is now being considered for coverage under the British Columbia Ministry of Health’s PharmaCare program. By filling out a questionnaire on a website called Your Voice, you can provide direct feedback about denosumab for the treatment of osteoporosis in men.
You can give input if you are a male B.C. resident living with osteoporosis, a caregiver to someone with osteoporosis, or if your group represents people who live with osteoporosis.
The input is reviewed by the Drug Benefit Council, which then gives recommendations on whether a medication should be covered, and how, by BC PharmaCare. BC PharmaCare then makes a decision based on those recommendations and available resources. Policies and plans already in place also factor in the decision making process.
It is an opportunity for you to share your perspectives on medication decisions that affect you or someone you provide care for.